Clinical Trials in the UK / NCT07295717
Recruiting
Phase 1
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
NCT07295717 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Healthy Volunteers
Investigational drug(s) / intervention(s)
ALN-4285Placebo
ALN-4285: ALN-4285 will be administered SC
Placebo: Placebo will be administered SC
Study summary
The purpose of this study is to:
* evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers
* characterize the single-dose pharmacokinetics (PK) of ALN-4285
Eligibility
Inclusion Criteria:
* Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2
* Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator
Exclusion Criteria:
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
* Has total bilirubin \>ULN
* Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg
* Has an estimated glomerular filtration (eGFR) of \<90 mL/min/1.73m\^2 at screening
* Has received an investigational agent within the last 30 days or 5 half-lives
Primary outcome measure(s)
- Frequency of Adverse Events (AEs) — Up to Week 24
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Clinical Trial Site | London | United Kingdom | Recruiting |
More Alnylam Pharmaceuticals trials in the UK
Other trials for the same condition
Nasal Residency of HEX17
Starting soon
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Active, not recruiting
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07295717 on ClinicalTrials.gov ↗ ← All trials in the UK